Mezzion FY 2025 Annual ReportBeta
Mezzion annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Mezzion FY 2025 Annual Report Analysis
Business Overview
- • Udenafil-based Fontan patient treatment NDA planned resubmission after FDA protocol approval in March 2023, with ongoing additional clinical trials
- • ADPKD treatment with Udenafil entered preclinical stage in April 2025, collaborating with Mayo Clinic for efficacy evaluation
Management Discussion & Analysis
- • Revenue KRW 7.91B, down 8.2% YoY; Operating loss KRW 16.77B, up 17.3%; Net loss KRW 34.93B, up 79.3%
- • Decline in sales due to livestock epidemic impact; increased SG&A by KRW 2.01B from ongoing clinical trial costs
Risk Factors
- • No derivative contracts entered in FY2025
- • No market risk quantification disclosed in financial notes
Mezzion FY 2025 Key Financial MetricsDART
Total Assets
KRW 98.0B
▲ +32.5% YoY
Source: KIFRS consolidated financial data from Mezzion annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding